Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Fig. 2

Whole cohort estimates of PFS and OS and the annual hazard rate over time. A 75 of 190 (39.5%) patients in the P + C group and 78 of 102 (76.5%) patients in the CA group died. B 108 of 190 (56.8%) patients in the P + C group and 81 of 102 (79.4%) in the CA group experienced PD or death. C Whole cohort annual hazard rate for progression. D Whole cohort annual hazard rate for death. Abbreviations: OS, overall survival; PD-1/L1, agents that inhibit PD-1 or PD-L1; PFS, progression-free survival; HR, hazard ratio

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us